Sangamo Therapeutics Inc. (SGMO): This Small-Cap Stock Is Poised To Outperform in 2025
We recently compiled a list of the 15 Small-Cap Stocks Poised to Outperform in 2025. In this article, we are going to take a ...
Levi & Korsinsky Announces an Investigation on Behalf of Sangamo Therapeutics, Inc. (SGMO) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / January 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo ...
Hosted on MSN7d
SGMO Stock Crashes as Pfizer Ends Deal for Hemophilia Candidate
Sangamo Therapeutics SGMO stock crashed 60.4% after hours on Monday after it announced that its partner, Pfizer PFE, ...
PFE Returns Rights to Hemophilia A Candidate to Partner SGMO
PFE ends deal with SGMO for hemophilia A gene therapy candidate. NVS' gene therapy for SMA meets goal in study.
Business Wire4d
Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leadi…
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an ...
Benzinga.com7d
9 Analysts Have This To Say About Sangamo Therapeutics
9 analysts have shared their evaluations of Sangamo Therapeutics SGMO during the recent three months, expressing a mix of ...
Sangamo Therapeutics (NASDAQ:SGMO) Given “Buy” Rating at HC Wainwright
Sangamo Therapeutics (NASDAQ:SGMO – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at HC ...
Sangamo Therapeutics: Left At The Alter (Rating Downgrade)
Sangamo (SGMO) stock faces challenges as Pfizer terminates partnership for hemophilia A gene therapy, impacting share price ...
Morningstar5d
Sangamo Therapeutics, Inc. (SGMO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Law Offices of Howard G. Smith announces an investigation on behalf of Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) (NASDAQ: SGMO) investors concerning the Company’s possible ...
Yahoo Finance3d
Sangamo Therapeutics, Inc. (SGMO)
RICHMOND, Calif., October 22, 2024--Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025 ...